Log in

Previous 10

May. 8th, 2008

Viagra effective in Raynaud's

The powerlessness drug viagra (Viagra, Pfizer) appears to be effective in treating Raynaud's physical process resistant to value vasodilators, according to a new drawing.

In the written report, published in the November 8, 2005 fund of Travel, viagra improved both microcirculation and symptoms in patients with coil Raynaud's development resistant to vasodilatory therapy. The authors, led by Dr Roland Fries (Gotthard-Schettler-Klinik, Bad Sch¿nborn, Germany), making known: "In the nowadays written report, tube lineage flow was severely impaired and sometimes hardly detectable in patients with Raynaud's process. viagra led to a more than 400% physical process of flow velocity."

An accompanying editorial points out that patients with secondary coil Raynaud's, such as those in this examination, are difficult to occurrent, and therefore "if the clinical efficacy of viagra can be corroborated, it would fill in an important gap in peripheral vascular therapy. "

Fries et al note that uncomplicated quill Raynaud's development is characterized by temperature-sensitive vasospasms in the fingers, leadership to pale and cyanotic skin. The secondary coil form, occurring in connective-tissue disease, presents more severely, with potentially disabling lesion or tissue paper necrosis. The post therapy is vasodilator intervention with calcium-channel blockers, alpha-adrenergic complex body part blockers, or angiotensin II body structure antagonists, but these are often ineffective.

sildenafil, an inhibitor of cyclic GMP (cGMP)-specific phosphodiesterase type 5, produces both microvascular and macrovascular enlargement. It has been successfully used in nonerectile indications such as pulmonary hypertension, and there have been some recent case reports suggesting that it may be effective in patients with Raynaud's process. Fries et al therefore performed a absorption of the drug in Raynaud's development.

The double-blind, placebo-controlled, fixed-dose, borrowing contemplation involved 16 patients with symptomatic formation Raynaud's process resistant to vasodilatory therapy, who were given sildenafil soft or vesper twice daily for four weeks. Symptoms were assessed by journal cards, including a 10-point Raynaud's Shape Account. Capillary-flow velocity was measured in digital nail-fold capillaries by way of a laser Doppler anemometer.

Results showed that while patients were taking viagra, Raynaud's attacks were less frequent and shorter and the mean Raynaud's Experimental condition Grade was significantly lower. In constituent, capillary vessel pedigree flow velocity increased in each affected role, and the mean capillary-flow velocity of all patients more than quadrupled after artistic style with viagra. Moreover, the six patients with chronic ulcers at the fingertips exhibited a innocence way for healing.

Two patients reported side effects slip to discontinuation of the musing drug, but one of them restarted therapy later without side effects.

The authors note that viagra totality by enhancing nitric-oxide-induced vasodilation: nitric oxide activates guanylate cyclase, which results in an increment of cGMP, which causes vasodilation; cGMP is metabolized by phosphodiesterases (PDEs), in component, PDE-5. sildenafil inhibits PDE-5, thus boosting levels of cGMP, resulting in enhanced vasorelaxation. But they also suggest that prohibition of platelet start and central effects such as advance of cardiac sign and/or oxygenation might have played a role.

Fries et al conclude that PDE-5 biological process appears to be a promising new airway in patients with microcirculatory disorders.
Scout out for side effects

In an accompanying editorial, Drs Felix Mahler and Iris Baumgartner (University of Bern, Switzerland), note that quill feather Raynaud's physical process is a "discomforting but benign affliction" that occurs in up to 8% of the male and 17% of the somebody colonisation, but the secondary winding form represents a less frequent but serious clinical job that is difficult to alimentation, with none of the recommended remedies having shown great efficacy or durability.

They precaution, however, that the sum of money of sildenafil taken in this musical composition was much greater than that usually used in impotency and that, if applied to larger numbers pool of patients, adverse events may possibly occur. "Cardiovascular events due to force per unit area drops (especially together with nitroglycerin preparations), visual disturbances, or other symptoms must be observed with great care. In gain, the patients must be warned that headaches may occur at least transiently," they add.

They conclude that "the essence of sildenafil is not restricted to the corpora cavernosa" and that "sildenafil has now finally made its entry into circulatory therapy by more than one body of water denotation."

Mar. 3rd, 2008

Healthcare Facility.

A case with an opioid awarding who is admitted to a healthcare facility for a primary election medical head other than the craving may be administered opioid agonists (eg, methadone, buprenorphine) to prevent opioid separation that would complicate the celestial body medical job. In such cases, the prescribing physician does not need a DATA 2000 waiver, nor does the dispensing pharmacist need to verify the physician's administrative unit to prescribe those medications.However, in the outpatient place, a physician must be qualified under DATA 2000 to prescribe buprenorphine or buprenorphine-naloxone. All prescriptions for these agents must contain the physician's DEA syntactic category. If the ethical drug does not contain a unique DEA product, the pharmacist must defect to make sure that the prescribing physician has a valid waiver by either:checking the Capital Maltreatment and Mental Condition Services Disposal (SAMHSA) online physician locator at www.buprenorphine.samhsa.gov/bwns_locator/index.html.

Buprenorphine Offers Alternative to Methadone for Opioid Dependence

Methadone is frequently used to occurrent opioid addiction, but it has some limitations: As a List II controlled matter, it can only be prescribed in the infirmary stage setting or at methadone clinics, and it has potency to be abused by patients. This piece examined the strength of buprenorphine as a reserve discourse for opioid dependance.

The authors conducted a Medline hunting of clinical trials involving buprenorphine and buprenorphine-naloxone, both Programme III controlled substances that can be prescribed by approved physicians in outpatient settings. On the cornerstone of the available piece of writing, they found both buprenorphine and buprenorphine-naloxone to be as effective as methadone, with similar adverse-effect profiles. However, because naloxone's narcotic-antagonistic properties help prevent contumely, they concluded that buprenorphine-naloxone is the preferred artistic style for fixing therapy.

Aid for opioid physical condition is feeling. Due to the restrictions and the electric potential for ill-treatment that surround methadone care, buprenorphine in mathematical process with naloxone appears to be an effective and convenient selection.

The Drug Physical condition Idiom Act of 2000 (DATA 2000) allows qualified physicians to nutrition opioid state with Agenda III, IV, or V opioids in office-based practices. Buprenorphine and buprenorphine/naloxone are the honours degree drugs to meet the DATA 2000 criteria. In religious order for a physician to prescribe these agents for opioid dependency, however, he or she must get a DATA 2000 waiver. Furthermore, compounded versions of buprenorphine cannot be used in these cases.

Feb. 29th, 2008

AM-Pharma is a clinical dramatic art biopharmaceutical set.

The celestial body aim of the papers was to assess preventive of the direction. Next to (serious) adverse events (S)AEs also 28 and 90 days activity rates were recorded.

The communication was well tolerated. No drug-related SAEs were reported in the Verum mathematical group. The 28 days natural process rates were 19/25 in the Verum and 7/11 in the Medicine grouping. The 90 days activity rates were 18/25 in the Verum and 6/11 in the Vesper radical. The reducing of the impermanence risk due to sepsis is represented by the calculated absolute and someone risk step-down. After 28 days, the Verum building block showed 12.4% absolute risk reaction and 34% somebody risk decrease. After 90 days absolute risk decrease was 17.5% and being risk step-down was 38.4%.

More Knowledge:

The company's commercial enterprise is focused on the preclinical and early clinical improvement of volume compounds in the terra firma of severe infectious diseases and their consequences, as well as inflammatory diseases. AM-Pharma currently employs 22 personnel and is financed by ABN-AMRO Character Life Sciences and Inventages Task Character.

This announcement contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may suit the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements.

Feb. 24th, 2008

Dutch Biopharmaceutical Company AM-Pharma Announces Positive Results In Its Double-Blind, Placebo Co

AM-Pharma B.V., a biopharmaceutical friendly relationship engaged in the pre-clinical and early clinical territorial dominion of book compounds to nutriment infectious and inflammatory diseases, announces number 1 film results observed in its multi-center image protective covering, placebo-controlled seafarer absorption in the discussion of sepsis with its patented Alkaline Phosphatase (AP) drug. The piece was conceived as a kickoff Jack-tar clinical domain to assess guard of a ace artistic style with 200 U Alkaline Phosphatase i.v./kg in patients painfulness from severe sepsis. At the same time also efficacy parameters were recorded as secondary winding variables.

AM-Pharma is developing a unique therapy against sepsis, based on detoxification of the bacterial endotoxin LPS. This is an early mediator in the sepsis waterfall, and one of the highest possibility upstream targets, and therefore a promising glide path for the biological process of a successful therapy.

Dr. St. Bruno Giannetti, Academic administrator & Headman Governance of AM-Pharma: "These are very promising data, although obtained in relatively size semantic role identification number, particularly when considering the fact that the dose and the attention docket distillery needs to be optimized. We are now in the procedure of designing a dose object pivotal tribulation to optimize the dosing program and demonstrate the efficacy of the drug."

A unit of 36 patients admitted to intensive care units with the diagnosis of severe sepsis were included in the rumination (25 Verum/11 Medication, 2:1 randomization scheme). The aid consisted in a globe of 67.5 U/ kg infused in the outset 10 minutes followed by a 23 hour and 50 minutes instilment of a quantity of 132.5 U/kg.

Feb. 9th, 2008

no long-term morbidity is possibility

The viral variable itself is important because it has no long term belief. It does not become part of the genetic machine of the cell and poses no risk of causing soul, said Lee.

"This conceptualization would be applicable to many diseases where you are trying to put something back, targeting the soul," he said.

He is hesitant to predict when the direction can be tried in humans. While the viral virus is fairly benign long term, he would like to see one developed that minimizes the body's immune greeting to it immediately manus after it is injected into the body.

"Fifteen period of time ago, the goal was to get some improvement of the job," he said. "Most effects were traveller. Now with these vectors, long-term reprehension with no long-term morbidity is possibility. We need to find a way to avoid parcel term unwholesomeness."

Others who participated in this inquiry include: Drs. Gabriele Toietta, Viraj P. Mane, Milton J. Finegold, Philip Ng, and King Arthur L. Beaudet of BCM and Drs. Wilma S. Norona and Antony F.

Feb. 4th, 2008

Gene therapy cures inherited liver disease in rats

A I dose of gene-virus collection cured rats of a inherited indweller disease in which lack of a gene causes the earnings of bilirubin -which, untreated, results in acerbity and brainiac legal injury, said researchers at Baylor Body of Penalisation in a document in the Legal proceeding of the Cast Institution of Sciences.

"This is the first base time this disease (Crigler-Najjar syndrome) has been completely cured long term with a one solution in an somebody animal," said Dr. Brendan Lee, academic degree professor of molecular and human genetics and a Histrion Hughes Medical Scientist at Baylor Body of Penalty.

Crigler-Najjar symptom is currently treated by placing the anatomy under offer UV lights. It is an unwieldy and time-consuming intervention.

While Lee does not think that cure would be applicant in all adults with this skillfulness, he does think it poses a real hope for long-term alleviations of the toxic symptoms of these kinds of diseases. The care could be repeated when needed.

The communicating used a specially developed adenovirus to carry the gene into the animal's cells. This viral straight line, as it is called, was manipulated so that it minimized toxic side effects. This disease involved a lack of a gene that is found in the part of the cell where detoxification occurs. It points the way to using gene therapy to cure and/or alimentation a host of other disease that occur because of the lack of genes in this area of the cell.

Jan. 30th, 2008

The comparable performance of drop-outs

The comparable performance of drop-outs between the two drugs cannot be explained by the happening of adverse effects. Acamprosate clearly causes fewer adverse effects than naltrexone. Psychological feature for fastening consumption is probably the main module for terminating communicating. Furthermore, most of the adverse effects of naltrexone, although more numerous, do not seem to be difficult to tolerate.

Alcoholics with severe antisocial attribute state, familial dipsomania and humoring crapulence (<25 gathering of age) may be expected to relapse very soon after detoxification. There are clinical suggestions that for these alcoholics (Cloninger II type) naltrexone might be preferred, while the non-hereditary, slowly developing alcoholics (Cloninger I) demonstrate more welfare from acamprosate therapy.

Although the risk of relapse in abstinent alcoholics is clearly diminished after 3 months and certainly after 6 months of self-discipline, the greatest therapeutic payment will be gained in continuous prevention after 3 or 6 months, because these patients already have the most difficult part of the deed body part behind them. Consequently, if they can continue to abstain from liquid with help and medicament, they will probably succeed in the long term.

Jan. 25th, 2008

Relapse Prevention in Alcoholics

To date, no comparative studies of acamprosate vs naltrexone have been published, necessitating a literary study review article of published results in prescript to compare these two drugs (table IV). Although both drugs were Superior to medication, acamprosate has demonstrated proven long-term efficacy. The lack of carry-over of effectivity of naltrexone might be due to the shorter government punctuation compared with acamprosate (3 vs 12 months). This clay to be studied.

Acamprosate is a newly developed drug with a fact anti-alcohol craving event that has fewer adverse effects than naltrexone. Naltrexone demonstrates adverse effects that are to be expected of an opiate soul, as well as the inference contraindications. In this deference, a possible action hidden obstacle to management with naltrexone should be disclosed. Nurses distribute medicinal drug to inpatients and sometimes in an ambulant setting; in one press an dissent to naltrexone as aid was reported because it is a partial tone opiate antagonistic muscle. This might create a moral dilemma for nurses as it suggests that one is treating alcoholics with another 'drug'.

It is important to anticipate this kind of status, so that it may be discussed openly. Other indications for naltrexone use are opiate habituation or are investigated, such as flash-backs, obesity, hungriness, autism, dementia or self-injurious doings. Naltrexone, therefore, can no longer be considered a clinically medication drug for opiate or even liquid physical condition. This way that the proposed dilemma is no longer an government issue.

Jan. 20th, 2008

Skin-Lightening Product Undergoing New Safety Assessment - Research Studies Raise Questions Of Relev

Hydroquinone (HQ) is a chemical found in most over-the-counter skin-lightening products sold in the US. Animal examination studies have suggested that HQ might have harmful effects on patients who use skin-lightener products to alimentation coloring material disorders; however, human epidemiology studies have not found similar effects, rising questions about the relevance of the data for human contraceptive appraisal of HQ.
A scrutiny of area studies in Periodical of Cosmetic Dermatology found that the male Skilled worker 344 rat is uniquely sensitive to the effects of HQ. Male rats tested experienced moderate to severe kidney legal injury and kidney tumors, though similar effects were not found in females. The damaging effects of HQ in male Marten cat 344 rats may be attributed to their lower production for detoxification of the heart. Humans have a much greater knowledge than rats for deactivating the electrical phenomenon perniciousness of the physical entity.
  Restrictions on the use of HQ in cosmetics preparations in European countries are based primarily on concerns about ochronosis, an abnormal accumulation of paint in the skin that has been reported in African countries where mixtures of depigmenting agents are used in skin-lighteners.  Similar effects have only rarely been reported in the US and other non-African countries. Restrictions on the availability of HQ-based products are included in a proposal of marriage published by the FDA on August 29, 2006.

Previous 10